Supriya Lifescience Ltd
Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.[1]
- Market Cap ₹ 6,016 Cr.
- Current Price ₹ 748
- High / Low ₹ 842 / 556
- Stock P/E 33.0
- Book Value ₹ 134
- Dividend Yield 0.13 %
- ROCE 27.5 %
- ROE 20.8 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| 184 | 213 | 278 | 312 | 391 | 530 | 461 | 570 | 696 | 715 | |
| 166 | 191 | 213 | 213 | 218 | 316 | 332 | 394 | 436 | 457 | |
| Operating Profit | 17 | 22 | 65 | 98 | 173 | 214 | 129 | 176 | 261 | 258 |
| OPM % | 9% | 10% | 23% | 32% | 44% | 40% | 28% | 31% | 37% | 36% |
| 7 | 9 | 8 | 11 | 5 | 8 | 9 | 11 | 10 | 10 | |
| Interest | 12 | 11 | 10 | 7 | 4 | 4 | 3 | 5 | 2 | 2 |
| Depreciation | 5 | 5 | 5 | 6 | 7 | 10 | 12 | 16 | 20 | 24 |
| Profit before tax | 8 | 14 | 57 | 96 | 167 | 207 | 123 | 166 | 248 | 242 |
| Tax % | 30% | 40% | 31% | 24% | 26% | 27% | 27% | 28% | 24% | |
| 6 | 9 | 39 | 73 | 124 | 152 | 90 | 119 | 188 | 182 | |
| EPS in Rs | 3.87 | 5.96 | 26.93 | 50.11 | 16.89 | 18.86 | 11.17 | 14.80 | 23.35 | 22.66 |
| Dividend Payout % | 0% | 0% | 0% | 20% | 3% | 3% | 5% | 5% | 4% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | 10% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 7% |
| TTM: | 16% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 44% |
| 1 Year: | -4% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 23% |
| 3 Years: | 17% |
| Last Year: | 21% |
Balance Sheet
Figures in Rs. Crores
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15 | 15 | 15 | 15 | 15 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 31 | 40 | 79 | 134 | 254 | 600 | 683 | 799 | 981 | 1,066 |
| 140 | 130 | 90 | 82 | 72 | 27 | 22 | 5 | 5 | 5 | |
| 55 | 60 | 69 | 105 | 105 | 92 | 98 | 101 | 110 | 116 | |
| Total Liabilities | 241 | 245 | 253 | 336 | 445 | 735 | 820 | 921 | 1,112 | 1,203 |
| 89 | 91 | 85 | 99 | 100 | 190 | 262 | 310 | 453 | 458 | |
| CWIP | 36 | 34 | 35 | 40 | 79 | 43 | 68 | 149 | 148 | 172 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 64 | 63 | 57 |
| 117 | 120 | 133 | 197 | 267 | 502 | 466 | 399 | 448 | 516 | |
| Total Assets | 241 | 245 | 253 | 336 | 445 | 735 | 820 | 921 | 1,112 | 1,203 |
Cash Flows
Figures in Rs. Crores
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| 27 | 28 | 49 | 117 | 76 | 49 | 64 | 113 | 165 | |
| -27 | -5 | 5 | -25 | -47 | -60 | -124 | -174 | -152 | |
| -2 | -20 | -50 | -29 | -15 | 150 | -10 | -22 | -8 | |
| Net Cash Flow | -2 | 3 | 4 | 62 | 15 | 139 | -70 | -83 | 4 |
Ratios
Figures in Rs. Crores
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 99 | 92 | 79 | 60 | 69 | 79 | 67 | 71 | 70 |
| Inventory Days | 113 | 85 | 77 | 130 | 206 | 172 | 234 | 140 | 205 |
| Days Payable | 121 | 112 | 110 | 130 | 145 | 91 | 130 | 98 | 129 |
| Cash Conversion Cycle | 91 | 64 | 45 | 61 | 130 | 160 | 171 | 114 | 146 |
| Working Capital Days | -69 | -50 | -5 | -40 | 28 | 117 | 168 | 157 | 144 |
| ROCE % | 14% | 37% | 50% | 60% | 43% | 19% | 22% | 27% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
26 Nov - The officials of our Company, Supriya Lifescience Limited ('Company') will be interacting with Analyst/Institutional Investors on Tuesday, December 2, 2025 as per details attached herewith. …
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
18 Nov - Transcript of the Earnings Call for the Unaudited Financial Results for the quarter and half year ended September 30, 2025, is enclosed herewith. Kindly take …
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
13 Nov - Newspaper Publication for the Unaudited Financial Results for the Quarter and Half year ended September 30, 2025 is enclosed herewith.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
13 Nov - Audio recording of Nov 13, 2025 earnings call for quarter and half-year ended Sep 30, 2025 posted online.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
13 Nov - Supriya Lifescience Q2 FY26: Revenue Rs199.83cr (+20.3%); PAT Rs50.43cr; EBITDA Rs72.65cr; capacity 78%.
Annual reports
Concalls
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT REC
-
May 2025Transcript PPT REC
-
Jan 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT REC
-
Jun 2024Transcript PPT REC
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT REC
-
Jun 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
May 2022TranscriptNotesPPT
-
Feb 2022TranscriptPPT
-
Jan 2022Transcript PPT
Niche Products Offerings[1]
Supriya Lifescience Ltd. has a niche product basket of 40+ APIs and is a global leader in Anti-histamines, anti-allergy, Vitamins, Anti-Asthmatics, & Anesthetics. They utilize a backward-integrated model for 15 products and possess the ability to handle complex chemistries and controlled substances.